Curriculum vitae

Name:	John-John Bryan Schnog
Date of birth:	February 5th 1974
Place of Birth:	Curaçao, Netherlands Antilles
Marital status:	Married
Profession:	Internist (registered April 1st 2006) Hematologist (registered August 6th 2008) Medical oncologist (registered January 29th 2009)
BIG:	89051528101

High-school: Peter Stuyvesant College Curaçao, Netherlands Antilles (1986-1992)

Medical studies: University Hospital Leiden, the Netherlands (1992-1997)

Rotations the Sint Elisabeth Hospital, Curaçao, Netherlands Antilles (1998-1999)

Medical degree obtained at the University of Groningen, the Netherlands (October 1999)

April 1st 2000-March 31st 2006: Residency Internal Medicine in the Slotervaart Hospital Amsterdam (Dr. D.P.M. Brandjes, internist), the Academic Medical Center Amsterdam (Prof. Dr. P. Speelman, internist and Prof. Dr. M. Levi, internist) and at the Antoni van Leeuwenhoek Cancer Center in Amsterdam (Prof. Dr. S. Rodenhuis).

May 1st 2006 – April 30th 2008: Fellowship hematology in the Erasmus Medical Center, Rotterdam, The Netherlands (Prof. Dr. B. Löwenberg)

May 1st 2008 – October 31st 2008: Completion fellowship oncology in the Academic Medical Center, Amsterdam, The Netherlands (Prof. Dr. D. Richel)

Research experience: From 1996 active in researcher on sickle cell disease. Co-founder of CURAMA in 2004 (Curaçao-Rotterdam-Amsterdam-Maastricht en Anderen), which is a collaborative effort studying sickle cell disease in the Netherlands and Netherlands Antilles.

Thesis: Defended thesis 'Cum laude' at the University Hospital Groningen. Title: 'Studies on the pathophysiology, disease severity assessment and management of sickle cell disease' (June 30th 2004).

Awards: Hematology thesis of the year award 2005 (received from the Netherlands Society of Hematology)

Research abstract oral presentation award 2008 (received from the Netherlands Society of Internal Medicine)

Lectures: Various educational lectures at NASKHO (Netherlands Antilles for Higher Clinical Education) meetings.

Educational session at 2010 European Hematology Association meeting in Barcelona entitled 'Hypercoagability in sickle cell disease'.

Memberships: Nederlandse Internisten Vereniging (NIV)
European Society of Medical Oncology (ESMO)
Nederlandse Vereniging voor Hematologie (NVvH)
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
European Hematology Association (EHA)

Co-promotor:

Thesis E. van Beers (2008): Sickle cell disease; pathophysiology and clinical complications.
Thesis P. Landburg (2013): ADMA, Angiogenesis and clinical complications in sickle cell disease.

List of publications:

Books

Contributing author of: Lang, Florian (Ed.). Encyclopedia of Molecular Mechanisms of Human Disease. 2009, ISBN: 978-3-540-67136-7.

Contributing author of: More Attention for Care. M.A.C. Foundation, ISBN: 978-99904-1-205-5.

Editor and main contributing author of: *Schnog JB*, Brandjes DPM, Duits AJ, Rojer RA, Muskiet FD eds. Sikkelcelziekte; een praktische handleiding. Van Zuiden Publishers 2006, ISBN: 90-8523-110-8

Scientific papers

Gerrits EG, *Schnog JB*. An unusual craving! Neth J Med. 2015;73(2):96.

Schimmel M, van Beers EJ, van Tuijn CF, Nur E, Rijneveld AW, Mac Gillavry MR, Brandjes DP, *Schnog JB*, Biemond BJ; on behalf of the CURAMA study group. N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. Am J Hematol. 2015, Epub ahead of print.

Schimmel M, Nur E, Biemond BJ, van Mierlo GJ, Solati S, Brandjes DP, Otten HM, *Schnog JB*, Zeerleder S. Nucleosomes and neutrophil activation in sickle cell disease painful crisis. Haematologica 2013;98:1797-803.

E Nur, DP Brandjes, T Teerlink, HM Otten, RPJ Oude Elferink, F Muskiet, LM Evers, H ten Cate, BJ Biemond, AJ Duits, *JB Schnog* on behalf of the CURAMA study group. N-acetylcysteine Reduces Oxidative Stress in Sickle Cell Patients. Ann Hematol 2012;91(7):1097-105.

E Nur, BJ Biemond, HM Otten, DP Brandjes, *JB Schnog* on behalf of the CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol. 2011;86:484-9.

E Nur, M Verwijs, DR de Waart, *JB Schnog*, HM Otten, DP Brandjes, BJ Biemond, RP Elferink on behalf of the CURAMA Study Group. Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes. Biochim Biophys Acta 2011;1812:1412-7.

E Nur, EJ van Beers, S Martina, I Cuccovillo, HM Otten, *JB Schnog*, JCM Meijers, A Mantovani, DP Brandjes, B Bottazzi, BJ Biemond on behalf of the CURAMA Study Group. Levels of Pentraxin-3, an Acute Phase Protein, Are Increased During Sickle Cell Painful Crisis. Blood Cells Mol Dis 2011;46:189-94.

E Nur, W Mairuhu, BJ Biemond, AP van Zanten, *JB Schnog*, DP Brandjes, HM Otten HM; CURAMA study group. Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. Am J Hematol 2010;85:902-4.

E Nur, DP Brandjes, *JB Schnog*, HM Otten, K Fijnvandraat, CG Schalkwijk, BJ Biemond BJ; CURAMA Study Group. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. Br J Haematol 2010;151:62-9.

CF van Tuijn, EJ van Beers, *JB Schnog*, Biemond BJ. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol 2010;85:532-5.

PP Landburg, T Teerlink, BJ Biemond, DP Brandjes, FA Muskiet, AJ Duits, *JB Schnog* on behalf of the CURAMA study group. Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells Mol Dis 2010;44:229-32.

EJ Van Beers, BJ Biemond, *JB Schnog* on behalf of the CURAMA Study Group. Letter in response to "Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocity". Am J Hematol. 2010;85:217.

PP Landburg, E Nur, N Maria, DP Brandjes, BJ Biemond, *JB Schnog*, AJ Duits on behalf of the CURAMA Study Group. Elevated circulating stromal-derived factor-1 levels in sickle cell disease. Acta Haematol. 2009;122:64-9.

LJ van Tits, WL van Heerde, PP Landburg, MJ Boderie, FA Muskiet, N Jacobs, AJ Duits, *JB Schnog*. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun. 2009;390:161-4.

RT van Beem, E Nur, JJ Zwaginga, PP Landburg, EJ van Beers, AJ Duits, DP Brandjes, I Lommerse, HC de Boer, CE van der Schoot, *JB Schnog* and BJ Biemond on behalf of the CURAMA study group. Elevated endothelial progenitor cells during painful sickle cell crisis. Exp Haematol,2009;37:1054-9.

MH Strijbos, PP Landburg, E Nur, T Teerlink, FW Leebeek, AW Rijneveld, BJ Biemond, S Sleijfer, JW Gratama, AJ Duits, *JB Schnog* on behalf of the CURAMA study group. Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? Blood Cells Mol Dis. 2009;43:63-7.

PP Landburg, H Elsenga, *JB Schnog*, AJ Duits on behalf of the CURAMA Study Group*. Increased serum levels of anti-angiogenic factors soluble FMS-like tyrosine kinase and soluble endoglin in sickle cell disease. Acta Haematol 2008;120:130-3.

K Berend, VGM Abreu de Martinez, *JB Schnog*. An unusual way of diagnosing sickle cell disease. Am J Hematol 2009;84:371.

EJ van Beers, E Nur, CM Schaefer-Prokop, MR Mac Gillavry, JWJ van Esser, DPM Brandjes, MC Kappers-Klunne, AJ Duits, FAJ Muskiet, *JB Schnog*, BJ Biemond on behalf of the CURAMA study group. Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. Am J Hematol 2008;83:850-4.

PP Landburg, T Teerlink, FAJ Muskiet, JWJ van Esser, MR Mac Gillavry, BJ Biemond, DPM Brandjes, AJ Duits, *JB Schnog* on behalf of the CURAMA study group. Association of asymetric dimethylarginine concentrations with pulmonay hypertension in sickle cell disease. Haematologica 2008;93:1410-2.

RM Van Hest, *JB Schnog*, MB Van 't Veer, JJ Cornelissen. Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib. Am J Hematol 2008;83:757-8.

PP Landburg, T Teerlink, FAJ Muskiet, AJ Duits, *JB Schnog* on behalf of the CURAMA study group. Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide inhibitor, are elevated in sickle cell disease but do not increase further during painful crises. Am J Hematol 2008;83:577-9.

E.J. van Beers, van Oerle R, Brandjes DPM, Duits AJ, van Esser JWJ, ten Cate H, Biemond BJ, *Schnog JB* on behalf of the CURAMA study Group. No Association of the Hypercoagulable State With Sickle Cell Disease Related Pulmonary Hypertension. Haematologica 2008;93:e42-e44.

EJ van Beers, CFJ van Tuijn, A van der Giessen, *JB Schnog*, BJ Biemond on behalf of the CURAMA study group. High prevalence of sickle cell disease related organ damage occurs irrespective of pain rate; implications for clinical practice. Haematologica 2008;93:757-60.

EJ van Beers, M Nieuwdorp, AJ Duits, LM Evers, *JB Schnog*, BJ Biemond on behalf of the CURAMA study group. Sickle cell patients are characterized by a reduced glycocalyx volume. Haematologica. 2008;93:307-8.

EJ van Beers, BLF van Eck-Smit, MR Mac Gillavry, CFJ van Tuijn, JWJ van Esser, DPM Brandjes, MC Kappers-Klunne, AJ Duits, BJ Biemond, *JB Schnog* on behalf of the CURAMA study group. Large and medium sized pulmonary artery obstruction does not play a role of primary importance in the etiology of sickle cell disease related pulmonary hypertension. Chest. 2008;133:646-52.

AJ Duits, T Rodriguez, *JB Schnog* on behalf of the CURAMA study group. Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease. Br J Haematol, 2006;134:116-119.

JB Schnog, JA Kremer Hovinga, S Krieg, S Akin, B Lämmle, DPM Brandjes, MR Mac Gillavry, FD Muskiet, AJ Duits on behalf of the CURAMA study group. ADAMTS13 activity in sickle cell disease. Am J Hematol. 2006;81:492-498.

JB Schnog, T Teerlink, FPL van der Dijs, AJ Duits, FAJ Muskiet on behalf of the CURAMA study group. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol. 2005;84:282-286.

JB Schnog, T Teerlink, FPL van der Dijs, AJ Duits, FAJ Muskiet on behalf of the CURAMA study group. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol. 2005;84:282-286.

JB Schnog, AJ Duits, FAJ Muskiet, H ten Cate, RA Rojer, DPM Brandjes. Sickle cell disease: a general overview. Neth J Med. 2004;62:364-374.

JB Schnog, EH Jager, FPL van der Dijs, AJ Duits, H Moshage, FD Muskiet, FAJ Muskiet. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol. 2004;83:371-375.

JB Schnog, MR Mac Gillavry, AP van Zanten, JCM Meijers, RA Rojer, AJ Duits, H ten Cate, DPM Brandjes. Protein C and S and inflammation in sickle cell disease. Am J Hematol. 2004;76:26-32.

JB Schnog. Studies gericht op ziekte-inzicht, het bepalen van de ziekte-ernst en de behandeling van sikkelcelziekte. Ned Tijdschr Hematol 2004;1:198-200.

AJ Duits, RA Rojer, T van Endt, MR MacGillavry, H ten Cate, DP Brandjes, *JB Schnog*. Erythropoiesis and serum sVCAM-1 levels in adults with sickle cell disease. Ann Hematol. 2003;82:171-174.

JB Schnog, RA Rojer, MR Mac Gillavry, H Ten Cate, DP Brandjes, AJ Duits. Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol. 2003;82:109-113.

JB Schnog, MR Mac Gillavry, RA Rojer, JC Meijers, R Fijnheer, H ten Cate, DP Brandjes, AJ Duits. No effect of acenocoumarol therapy on levels of endothelial activation markers in sickle cell disease. Am J Hematol. 2002;71:53-55.

FP van der Dijs, MR Fokkema, DA Dijck-Brouwer, B Niessink, TI van der Wal, *JB Schnog*, AJ Duits, FD Muskiet, FA Muskiet. Optimization of folic acid, vitamin B(12), and vitamin B(6) supplements in pediatric patients with sickle cell disease. Am J Hematol. 2002;69:239-246.

JB Schnog, FP van der Dijs, MR Fokkema, FD Muskiet, FA Muskiet. Folate status assessment and folic acid supplements in sickle cell disease. J Pediatr Hematol Oncol. 2001;23:548.

Schnog JB, Kater AP, Mac Gillavry MR, Duits AJ, Lard LR, van Der Dijs FP, Brandjes DP, ten Cate H, van Eps LW, Rojer RA. Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study. Am J Hematol. 2001;68:179-183.

Schnog JB, Duits AJ. (Referaat) Ulcera cruris door behandeling van sikkelcelpatiënten met hydroxycarbamide? Ned Tijdschr Geneesk 2001;43:2099.

Schnog JB, Keli SO, Pieters RA, Rojer RA, Duits AJ. Duffy phenotype does not influence the clinical severity of sickle cell disease. Clin Immunol. 2000;96:264-268.

AP Kater, *JB Schnog*. (Referaat) Sulfasalazine mogelijk effectief bij sikkelcelziekte. Ned Tijdschr Geneesk 2001;34:145.

JB Schnog, FP van der Dijs, DA Brouwer, AJ Duits, FD Muskiet, FA Muskiet. Plasma homocysteine levels in sickle cell disease and the need for folate supplementation. J Pediatr Hematol Oncol. 2000;22:184-185.

AJ Duits, *JB Schnog*, LR Lard, AW Saleh, RA Rojer. Elevated IL-8 levels during sickle cell crisis. Eur J Haematol. 1998;61:302-305.

FP van der Dijs, *JB Schnog*, DA Brouwer, HJ Velvis, GA van den Berg, AJ Bakker, AJ Duits, FD Muskiet, FA Muskiet. Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol. 1998;59:192-198.

JB Schnog, LR Lard, RA Rojer, FP Van der Dijs, FA Muskiet, AJ Duits. New concepts in assessing sickle cell disease severity. Am J Hematol. 1998;58:61-66.